CNS Metastases in Patients With

Although Patients with pathologically confirmed, advanced non-small-cell lung cancers (NSCLC) harboring a Eighty-three patients with CNS metastases, including leptomeningeal disease, occurred in more than a third of patients with

Informations de copyright

© 2020 by American Society of Clinical Oncology.

Déclaration de conflit d'intérêts

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Michael OffinHonoraria: OncLive Consulting or Advisory Role: PharmaMar, Novartis, Targeted Oncology Travel, Accommodations, Expenses: Bristol Myers Squibb, Merck Sharp & DohmeJia LuoHonoraria: Targeted OncologyJordan DienstagStock and Other Ownership Interests: AbbVie, Bristol Myers Squibb, Thermo Fisher Scientific, AllerganCharles M. RudinConsulting or Advisory Role: AbbVie, Harpoon Therapeutics, Genentech, AstraZeneca, Ascentage Pharma, Bicycle Therapeutics, Celgene, Daiichi Sankyo, Ipsen, Loxo, PharmaMar, Bridge Medicines, Amgen, Jansen, Syros Pharmaceuticals Research Funding: AbbVie/Stemcentrx (Inst), Viralytics (Inst), Merck (Inst), Daiichi Sankyo (Inst), Genentech (Inst)Gregory RielyResearch Funding: Novartis (Inst), Genentech (Inst), GlaxoSmithKline (Inst), Pfizer (Inst), Infinity Pharmaceuticals (Inst), Mirati Therapeutics (Inst), Merck (Inst), Takeda (Inst) Patents, Royalties, Other Intellectual Property: Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst) Travel, Accommodations, Expenses: Merck Sharp & Dohme Other Relationship: Pfizer, Genentech, TakedaNatasha RekhtmanHonoraria: Physicians’ Education ResourceMaria E. ArcilaHonoraria: Invivoscribe, Biocartis Consulting or Advisory Role: AstraZeneca Travel, Accommodations, Expenses: AstraZeneca, Invivoscribe, Raindance TechnologiesGlenn HellerResearch Funding: Janssen DiagnosticsMarc LadanyiConsulting or Advisory Role: Bristol Myers Squibb, Bayer Research Funding: Loxo (Inst), Helsinn Therapeutics, Merus NV (Inst), Elevation Oncology (Inst)Bob T. LiConsulting or Advisory Role: Guardant Health, Hengrui Therapeutics, Eli Lilly (Inst), Genentech (Inst) Research Funding: AstraZeneca (Inst), GRAIL (Inst), Daiichi Sankyo (Inst), Hengrui Therapeutics (Inst), Guardant Health (Inst), Amgen (Inst), Eli Lilly (Inst), MORE Health (Inst) Patents, Royalties, Other Intellectual Property: US62/514,661 (Inst), US62/685,057 (Inst)Mark G. KrisConsulting or Advisory Role: AstraZeneca, Regeneron, Pfizer, Daiichi Sankyo Travel, Accommodations, Expenses: AstraZeneca, Pfizer Other Relationship: Memorial Sloan Kettering Cancer Center, Genentech Open Payments Link: https://openpaymentsdata.cms.gov/physician/markgkris/summaryPaul PaikHonoraria: Celgene, Takeda, Calithera Biosciences, Boehringer Ingelheim, EMD Serono, AstraZeneca Consulting or Advisory Role: Celgene, EMD Serono, Takeda, Calithera Biosciences, AstraZeneca, Boehringer Ingelheim Research Funding: Celgene, EMD Serono Travel, Accommodations, Expenses: EMD SeronoAlexander DrilonHonoraria: Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, MORE Health, Research to Practice, Foundation Medicine, Peerview Consulting or Advisory Role: Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech, Helsinn Therapeutics, BeiGene, Hengrui Therapeutics, Exelixis, Bayer, Tyra Biosciences, Verastem, Takeda/Ariad/Millennium, BerGenBio, MORE Health, Eli Lilly, Verastem, AbbVie, 14ner/Elevation Oncology, Remedica, Archer Biosciences, Monopteros Research Funding: Foundation Medicine Patents, Royalties, Other Intellectual Property: Wolters Kluwer (royalties for Pocket Oncology) Other Relationship: Merck, GlaxoSmithKline, Teva, Taiho Pharmaceutical, Pfizer, PharmaMar, Puma Biotechnology No other potential conflicts of interest were reported.